MaxCyte, Inc. (MXCT)

Market Cap	438.50M
Revenue (ttm)	45.60M
Net Income (ttm)	-35.74M
Shares Out	105.69M
EPS (ttm)	-0.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	847,215
Open	4.080
Previous Close	4.140
Day's Range	4.080 - 4.400
52-Week Range	3.165 - 5.550
Beta	1.16
Analysts	Strong Buy
Price Target	9.50 (+124.06%)
Earnings Date	Nov 6, 2024

About MXCT

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engin...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 143
• Stock Exchange: NASDAQ
• Ticker Symbol: MXCT
• Website: https://www.maxcyte.com

Financial Performance

In 2023, MaxCyte's revenue was $41.29 million, a decrease of -6.72% compared to the previous year's $44.26 million. Losses were -$37.92 million, 60.9% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for MXCT stock is "Strong Buy." The 12-month stock price forecast is $9.5, which is an increase of 124.06% from the latest price.

Price Target

$9.5

(124.06% upside)

Analyst Consensus: Strong Buy